Trials / Completed
CompletedNCT00092404
Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,210 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months – 18 Months
- Healthy volunteers
- Accepted
Summary
The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.
Detailed description
The duration of treatment is 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | measles, mumps, and rubella virus vaccine live | |
| BIOLOGICAL | Comparator: Measles, Mumps, and Rubella Virus Vaccine Live |
Timeline
- Start date
- 2001-12-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2004-09-27
- Last updated
- 2017-03-15
Source: ClinicalTrials.gov record NCT00092404. Inclusion in this directory is not an endorsement.